Gyre Therapeutics Inc.

Gyre Therapeutics reported second quarter 2026 revenue of $29.1 million and a GAAP basic loss per share of $0.12, while affirming its full-year 2026 revenue guidance of $100.5 to $111.0 million. The company's lead product ETUARY generated $28.0 million in sales, up from $23.5 million a year earlier, though total revenue dipped 2% due to the end of a collaboration agreement with Astellas Pharma. In May, China's Center for Drug Evaluation accepted the New Drug Application for F351 as a treatment for chronic hepatitis B-induced liver fibrosis, and Gyre closed its all-stock acquisition of Cullgen valued at approximately $300 million. Research and development expenses surged to $19.1 million from $8.4 million, driven by clinical trial costs and a milestone payment tied to the F351 application, contributing to a net loss of $14.3 million compared to a $2.2 million loss in the prior-year period.

Gyre Therapeutics has appointed three new members to its board of directors, effective August 1, 2026. The new directors are Chief Scientific Officer Yue Xiong, Maxwell Kirkby, and Claire Weston. Dr. Xiong will serve as a Class I director with a term expiring in 2028, Mr. Kirkby as a Class II director with a term expiring in 2029 and a seat on the Compensation Committee, and Dr. Weston as a Class III director with a term expiring in 2027 and a seat on the Audit Committee. The company stated the appointments expand its scientific, clinical development, and cross-border biopharmaceutical operating expertise as it advances its pipeline targeting fibrosis, cancer, inflammation, and pain.